Reference
Edwards C, et al. A case series of immunotherapy-induced blistering skin disease occurring in association with nivolumab [an antiprogrammed cell death (PD)-1 monoclonal antibody] and pembrolizumab (an anti-PD-ligand 1 monoclonal antibody). British Journal of Dermatology 177 (Suppl. 1): 24 abstr. CPC 14, Jul 2017. Available from: URL: http://doi.org/10.1111/bjd.15428 [abstract] - UnitedKingdom
Rights and permissions
About this article
Cite this article
Nivolumab/pembrolizumab. Reactions Weekly 1673, 282 (2017). https://doi.org/10.1007/s40278-017-37370-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-37370-4